GlassScriptPhysician profile
Lynda Tran
NPI 1942776240
$15,662.84
in general payments reported to CMS, 2019-2025
46 companies · $2,586 in 2025
The $2,586 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,110 · 2022: $1,900 · 2023: $2,959 · 2024: $5,109 · 2025: $2,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,379.19 |
| Education | $273.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,073.37 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $1,306.75 | 2021-2025 | Opdivo, Reblozyl, Pomalyst |
| Astellas Pharma US INC | $1,051.48 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Astrazeneca Pharmaceuticals LP | $933.03 | 2021-2024 | Calquence, Enhertu, Lynparza |
| Glaxosmithkline, LLC. | $866.05 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $797.38 | 2021-2025 | Lynparza, Keytruda, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $780.99 | 2022-2024 | Fruzaqla, Alunbrig, Iclusig |
| Celgene Corporation | $614.83 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $581.13 | 2023-2025 | Cabometyx |
| Daiichi Sankyo INC. | $492.62 | 2021 | |
| Pfizer INC. | $489.15 | 2021-2024 | |
| Amgen INC. | $413.22 | 2021-2023 | Lumakras, Kyprolis |
| Gilead Sciences, INC. | $355.91 | 2022-2024 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $315.86 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $315.68 | 2023-2025 | Erleada, Rybrevant |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynda Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.